Synthesis and antitumor activity of 3-[(methyl)bis(5-trialkylsilyl-furan-2-yl)silyl]propylamines

A. Kleemann, J. Engel, B. Kutscher, and D. Reichert, Pharmaceutical Substances, Thieme, Stuttgart and New York (2009). D. A. Erlanson and W. Jahnke (editors), Fragment-Based Approaches in Drug Discovery, Wiley-VCH, Weinheim (2006), p. 91. C. L. Bethea, S. J. Mirkes, A. Su, and D. Michelson, Psychoneuroendocrinology, 27, 431 (2002). C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo, W. E. Burak, Jr., J. A. O’Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, P. A. Ganz, E. R. Sauter, S. W. Beenken, W. E. Grizzle, J. P. Fruehauf, D. W. Arneson, J. W. Bacus, M. D. Lagios, K. A. Johnson, and D. Browne, Clin. Cancer Res., 10, 5403 (2004). P. N. Munster, Expert Opin. Invest. Drugs, 15, 317 (2006). M. Blagosklonny, Trends Pharmacol. Sci., 26, 77 (2005). F. Mollinedo, Expert Opin. Ther. Pat., 17, 385 (2007). S. R. Vink, A. H. van der Luit, J. B. Klarenbeek, M. Verheij, and W. J. van Blitterswijk, Biochem. Pharmacol., 74, 1456 (2007). A. Huston, X. Leleu, X. Jia, A.-S. Moreau, H. T. Ngo, J. Runnels, J. Anderson, Y. Alsayed, A. Roccaro, S. Vallet, E. Hatjiharissi, Y.-T. Tai, P. Sportelli, N. Munshi, P. Richardson, T. Hideshima, D. G. Roodman, K. C. Anderson, and I. M. Ghobrial, Clin. Cancer Res., 14, 865 (2008). P. Norman, Curr. Opin. Invest. Drugs (BioMed Cent.), 2, 428 (2001). J. A. McIntyre, J. Castaner, and P. A. Lesson, Drugs Future, 30, 771 (2005). M. Muhsin, J. Graham, and P. Kirkpatrick, Nat. Rev. Drug Discovery, 2, 515 (2003). J. A. Smith, A. Gaikwad, J. Yu, J. K. Wolf, J. Brown, L. M. Ramondetta, and C. F. Stewart, Cancer Chemother. Pharmacol., 62, 51 (2008). A. J. Barker, K. H. Gibson, W. Grundy, A. A. Godfrey, J. J. Barlow, M. P. Healy, J. R. Woodburn, S. E. Ashton, B. J. Curry, L. Scarlett, L. Henthorn, and L. Richards, Bioorg. Med. Chem. Lett., 11, 1911 (2001). H. Kantarjian, E. Jabbour, J. Grimley, and P. Kirkpatrick, Nat. Rev. Drug Discovery, 5, 717 (2006). S. L. Martin, A. McDowell, J. F. Lynas, J. Nelson, and B. Walker, J. Pharm. Pharmacol., 53, 333 (2001). A. R. Lera, W. Bourguet, L. Altucci, and H. Gronemeyer, Nat. Rev. Drug Discovery, 6, 811 (2007). I. R. Radford, Curr. Opin. Invest. Drugs (BioMed Cent.), 3, 492 (2002). A. Bilir, B. Erguven, G. Oktem, A. Ozdemir, A. Uslu, E. Aktas, and B. Bonavina, Int. J. Oncol., 32, 829 (2008). W. Shelly, M. W. Draper, V. Krishnan, M. Wong, and R. B. Jaffe, Obstet. Gynecol. Surv., 63, 163 (2008). C. K. Baumann and M. Castiglione-Gertsch, Drugs, 67, 2335 (2007). M. G. Voronkov, G. I. Zelchan, and E. Lukevics, Silicon and Life [in Russian], Riga (1978). E. Lukevits, V. Lūse, I. Zicmane, E. Liepiņš, M. Trušule, S. Ģērmane, I. Augustāne, V. N. Verovsky, N. G. Prodanchuk, S. E. Deineka, and V. N. Nivalov, Khim. Geterotsikl. Soedin., 1653 (1991). [Chem. Heterocycl. Comp., 27, 1328 (1991)]. L. Ignatovich, V. Muravenko, I. Shestakova, I. Domrachova, J. Popelis, and E. Lukevics, Appl. Organomet. Chem., 24, 158 (2010). L. Ignatovich, V. Romanov, I. Shestakova, I. Domrachova, J. Popelis, and E. Lukevics, Khim. Geterotsikl. Soedin., 1791 (2009). [Chem. Heterocycl. Comp., 45, 1441 (2009)]. E. Lukevics and L. Ignatovich, in: M. Gielen and E. R. T. Tiekink (editors), Metallotherapeutic Drugs and Metal-Based Diagnostic Agents. The Use of Metals in Medicine, John Wiley and Sons, Chichester (2005), p. 83. W. Bains and R. Tacke, Curr. Opin. Drug Discovery Dev., 6, 526 (2003). M. Mägi, E. Lippmaa, E. Lukevics, and N. P. Erčak, Org. Magn. Reson., 9, 297 (1977). Report of the International Workshop on in vitro Methods for Assessing Acute Systemic Toxicity, NIH Publ. No: 01-4499 ( 2001), p. 12. D. J. Fast, R. C. Lynch, and R. W. Leu, J. Leukocyte Biol., 52, 255 (1992).